New hope for kids with tough cancers: first trial of Dual-Action cell therapy begins
NCT ID NCT07172958
Summary
This is a first-in-human safety study for a new, two-part cell therapy for children and young adults whose cancers have come back or haven't responded to standard treatments. Doctors will collect a patient's own immune cells, genetically modify them to better target the cancer, and infuse them back after a short course of chemotherapy. The main goal is to find the safest dose and see if the treatment is feasible for four types of childhood solid tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WILMS TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's National Hospital
RECRUITINGWashington D.C., District of Columbia, 20010, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Childrens National Hospital
NOT_YET_RECRUITINGWashington D.C., District of Columbia, 20010, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.